![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Deep sequencing analyses of minority baseline polymorphisms and persistence of emerging mutations in HCV genotype 1-infected patients treated with simeprevir
|
|
|
Reported by Jules Levin
EASL 2014 April 9-13 London, UK
Bart Fevery,1 Kim Thys,2 Veerle Van Eygen,1 Thierry Verbinnen,1 Elizabeth Van Rossem,2 Gaston Picchio,3 Sandra De Meyer,1 Oliver Lenz1
1Janssen Infectious Diseases, Beerse, Belgium; 2Janssen CREATE, Beerse, Belgium; 3Janssen Research & Development, LLC, Titusville, NJ, USA
![EASL1.gif](../images/041814/041714-2/EASL1.gif)
![EASL2.gif](../images/041814/041714-2/EASL2.gif)
![EASL3.gif](../images/041814/041714-2/EASL3.gif)
![EASL4.gif](../images/041814/041714-2/EASL4.gif)
![EASL5.gif](../images/041814/041714-2/EASL5.gif)
![EASL6.gif](../images/041814/041714-2/EASL6.gif)
![EASL7.gif](../images/041814/041714-2/EASL7.gif)
![EASL8.gif](../images/041814/041714-2/EASL8.gif)
![EASL9.gif](../images/041814/041714-2/EASL9.gif)
![EASL10.gif](../images/041814/041714-2/EASL10.gif)
![EASL11.gif](../images/041814/041714-2/EASL11.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|